Celldex Therapeutics - Recruiting 18 years or older. - An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma.
Rindopepimut (CDX-110) with GM-CSF; Temozolomide; KLH
Dr. Negrin University Hospital - Recruiting 18 years to 75 years. - Positron Emission Tomography With Fluoro-misonidazole (PET-FMISO) in High Grade Gliomas: Assessment of Tumor Hypoxia and Effect of Spinal Cord Stimulation.
18F-FMISO; PET without SCS; SCS; PET without/with SCS; Radiotherapy; Temozolomide
Duke University - Recruiting 18 years or older. - A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination With Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients Receiving a Temozolomide Based Regimen.
Bristol-Myers Squibb - Recruiting 18 years or older. - A Randomized Phase IIb, Open Label Study of Nivolumab or Nivolumab in Combination With Ipilimumab Versus Bevacizumab in Adult Subjects With Recurrent Glioblastoma (GBM).
Children's Oncology Group - Recruiting 3 years to 21 years. - A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children With Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial.
St. Jude Children's Research Hospital - Recruiting N/A to 21 years. - Molecular and Histopathologic Characterization of Atypical Teratoid Rhabdoid Tumors, Choroid Plexus Carcinomas, Ependymomas and Medulloblastoma/PNET of the Pediatric CNS.
National Cancer Institute (NCI) - Recruiting 18 years or older. - Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma.
Tocagen Inc. - Recruiting 18 years to 80 years. - A P1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extended-Release 5-FC.
Pediatric Brain Tumor Consortium - Recruiting 16 years to 21 years. - A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients With Refractory or Recurrent High Grade Gliomas (HGG).
Duke University - Recruiting 18 years or older. - A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination With Bevacizumab for Adult Patients With Recurrent Malignant Glioma Post-Bevacizumab Failure.
Rockefeller University - Recruiting 18 years or older. - A Phase I Study of Autologous Dendritic Cells Pulsed With Autologous Apoptotic Tumor Cells (DC/AAT) Administered Intradermally to Cancer Patients With Brain Tumors.
Spectrum Pharmaceuticals, Inc - Recruiting 2 years to 20 years. - Phase I Trial to Evaluate the Safety, Activity and Pharmacokinetics of Marqibo(Registered Trademark) (Vincristine Sulfate Liposomes Injection) in Children and Adolescents With Refractory Cancer.
National Cancer Institute (NCI) - Recruiting 1 year to 21 years. - A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma.
crizotinib; pharmacogenomic studies; pharmacological study
National Cancer Institute (NCI) - Recruiting 3 years to 30 years. - Study Of Reduced Dose Craniospinal Radiotherapy (1800 cGy) And Chemotherapy In Children With Newly-Diagnosed Standard-Risk Posterior Fossa Primitive Neuro-ectodermal Tumor (PNET/Medulloblastoma).